Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes-Reference-Cited by-同舟云学术

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

Published:2017-04-25 Issue:12 Volume:31 Page:2630-2641
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Hari P,Mateos M-V,Abonour R,Knop S,Bensinger W,Ludwig H,Song K,Hajek R,Moreau P,Siegel D S,Feng S,Obreja M,Aggarwal S K,Iskander K,Goldschmidt H

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2017122.pdf

Reference41 articles.

1. Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia 2014; 28: 981–992.

2. Attal M, Lauwers-Cances V, Hulin C, Facon T, Caillot D, Escoffre M et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). Blood 2015; 125: 391 (abstract).

3. Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol 2015; 1: 746–754.

4. Zimmerman TM, Griffith KA, Jasielec J, Rosenbaum CA, McDonnell K, Waite-Marin J et al. Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM). J Clin Oncol 2015; 33: Abstract 8510.

5. Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI et al. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant 2013; 19: 760–766.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway;Biomedicine & Pharmacotherapy;2023-08

2. Proteomic Alteration in the Progression of Multiple Myeloma: A Comprehensive Review;Diagnostics;2023-07-10

3. Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network;Frontiers in Oncology;2023-04-25

4. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation;Transplantation and Cellular Therapy;2023-02

5. Genome Instability in Multiple Myeloma: Facts and Factors;Cancers;2021-11-26